Literature DB >> 27737300

Risk Factors for Early Readmission After Anatomical or Reverse Total Shoulder Arthroplasty.

Shin Xu, Dustin K Baker, Justin C Woods, Eugene W Brabston, Brent A Ponce1.   

Abstract

Hospital readmissions are costly for patients and institutions. We conducted a study to evaluate rates of readmission within 30 days after anatomical total shoulder arthroplasty (ATSA) and reverse total shoulder arthroplasty (RTSA) and to determine independent risk factors for readmission. We queried the National Surgical Quality Improvement Program database for ATSAs and RTSAs performed between 2011 and 2013 and found a combined total of 3501 cases and an overall readmission rate of 2.7%. Of the readmissions, 67% were for medical complications, and 33% were for surgical complications. Of the medical complications, pneumonia was the most common (11.8%), followed by urinary tract infection (7.8%). Regarding surgical complications, surgical-site infection was the most common (13.7%), followed by prosthetic joint dislocation (9.8%). Hospital-acquired conditions, including surgical-site infection, urinary tract infection, deep vein thrombosis, and pulmonary embolism, accounted for 33% of all 30-day readmissions. Three independent risk factors for readmission were identified: revision surgery (odds ratio, 2.59), 3 or more comorbidities (odds ratio, 2.02), and extended length of stay (>4.3 days) during the index admission (odds ratio, 2.48). Other factors significantly (P < .05) associated with readmission were age over 75 years, dependent functional status, American Society of Anesthesiologists score of 4 or higher, cardiac comorbidity, 2 or more comorbidities, and urinary tract infection before discharge.

Entities:  

Mesh:

Year:  2016        PMID: 27737300

Source DB:  PubMed          Journal:  Am J Orthop (Belle Mead NJ)        ISSN: 1078-4519


  8 in total

1.  Drain Use is Associated with Increased Odds of Blood Transfusion in Total Shoulder Arthroplasty: A Population-Based Study.

Authors:  Jimmy J Chan; Carl M Cirino; Hsin-Hui Huang; Jashvant Poeran; Madhu Mazumdar; Bradford O Parsons; Shawn G Anthony; Leesa M Galatz; Paul J Cagle
Journal:  Clin Orthop Relat Res       Date:  2019-07       Impact factor: 4.176

2.  Comparison of patient-demographics, causes, and costs of 90-day readmissions following primary total shoulder arthroplasty for glenohumeral osteoarthritis.

Authors:  Marcos Vargas; Giovanni Sanchez; Adam M Gordon; Andrew R Horn; Charles A Conway; Afshin E Razi; Ramin Sadeghpour
Journal:  J Orthop       Date:  2022-03-31

3.  Subscapularis- and deltoid-sparing vs traditional deltopectoral approach in reverse shoulder arthroplasty: a prospective case-control study.

Authors:  Alexandre Lädermann; Patrick Joel Denard; Jérome Tirefort; Philippe Collin; Alexandra Nowak; Adrien Jean-Pierre Schwitzguebel
Journal:  J Orthop Surg Res       Date:  2017-07-14       Impact factor: 2.359

4.  Early outcomes of shoulder arthroplasty according to sex.

Authors:  Kelechi R Okoroha; Stephanie Muh; Michael Gabbard; Timothy Evans; Christopher Roche; Pierre-Henri Flurin; Thomas W Wright; Joseph D Zuckerman
Journal:  JSES Open Access       Date:  2019-03-16

5.  Delayed hospital discharge after total shoulder arthroplasty: why, and who is at risk?

Authors:  Mariano E Menendez; Sarah M Lawler; Michael P Carducci; David Ring; Kuhan A Mahendraraj; Andrew Jawa
Journal:  JSES Open Access       Date:  2019-09-17

Review 6.  Gender Influences on Shoulder Arthroplasty.

Authors:  Nicole J Hung; Stephanie E Wong
Journal:  Curr Rev Musculoskelet Med       Date:  2022-01-04

7.  Effect of complications on outcomes after revision reverse total shoulder arthroplasty.

Authors:  Robert Z Tashjian; Erin Granger; Kortnie Broschinsky; Jun Kawakami; Peter N Chalmers
Journal:  JSES Int       Date:  2020-06-10

8.  Sex differences in complications and readmission rates following shoulder arthroplasty in the United States.

Authors:  Brock M Knapp; Mina Botros; David C Sing; Emily J Curry; Josef K Eichinger; Xinning Li
Journal:  JSES Int       Date:  2020-02-29
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.